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Background: By the end of July 2021 Zimbabwe, has reported over 100,000 SARS-CoV-2 infections. The true
number of SARS-CoV-2 infections is likely to be much higher. We conducted a seroprevalence survey to esti-
mate the prevalence of past SARS-CoV-2 in three high-density communities in Harare, Zimbabwe before and
after the second wave of SARS-CoV-2.
Methods: Between November 2020 and April 2021 we conducted a cross-sectional study of randomly
selected households in three high-density communities (Budiriro, Highfield and Mbare) in Harare. Consent-
ing participants answered a questionnaire and a dried blood spot sample was taken. Samples were tested for
anti-SARS-CoV-2 nucleocapsid antibodies using the Roche e801 platform.
Findings: A total of 2340 individuals participated in the study. SARS-CoV-2 antibody results were available for
70¢1% (620/885) and 73¢1% (1530/2093) of eligible participants in 2020 and 2021. The median age was 22
(IQR 10-37) years and 978 (45¢5%) were men. SARS-CoV-2 seroprevalence was 19¢0% (95% CI 15¢1-23¢5%) in
2020 and 53¢0% (95% CI 49¢6-56¢4) in 2021. The prevalence ratio was 2¢47 (95% CI 1¢94-3¢15) comparing
2020 with 2021 after adjusting for age, sex, and community. Almost half of all participants who tested posi-
tive reported no symptoms in the preceding six months.
Interpretation: Following the second wave, one in two people had been infected with SARS-CoV-2 suggesting
high levels of community transmission. Our results suggest that 184,800 (172,900-196,700) SARS-CoV-2
infections occurred in these three communities alone, greatly exceeding the reported number of cases for
the whole city. Further seroprevalence surveys are needed to understand transmission during the current
third wave despite high prevalence of past infections.
Funding: GCRF, Government of Canada,Wellcome Trust, Bavarian StateMinistry of Sciences, Research, and the Arts
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The World Health Organization (WHO) declared the SARS-CoV-2
outbreak a global pandemic on March 11 2020, following theidentification of a cluster of cases of pneumonia, later termed COVID-
19, caused by a novel coronavirus (SARS-CoV-2), in Wuhan China in
December 2019 [1]. The first case of COVID-19 in Zimbabwe was con-
firmed on March 20 2020 in a resident who had returned from the
United Kingdom [2]. Zimbabwe has had two waves of infections with
peaks in early August 2020 and early January 2021 and is currently
experiencing a third wave (Figure 1).
Research in context
Evidence before this study
Many national and subnational population-based SARS-CoV-2
seroprevalence surveys have been conducted globally and sum-
marised in a recently published systematic review. Pooled esti-
mates of SARS-CoV-2 seroprevalence in the general population
varied greatly by WHO region with 19¢6% (95% CI 5¢5-33¢6, 4
studies), 6¢8% (95%CI 5¢0-8¢5, 13 studies), 4¢7% (95%CI 3¢6-5¢9,
14 studies) testing positive for SARS-CoV-2 antibodies in the
South East Asian, American and European regions respectively.
Overall the pooled estimated ratio of serologically detected
infections to confirmed cases of COVID-19 was 11¢1 (95%CI 8¢3-
14¢9) suggesting that for each virologically confirmed SARS-
CoV-2 infection, at least ten infections remained undetected by
surveillance systems globally. Only two population-based stud-
ies from Africa contributed to the systematic review reporting a
SARS-CoV-2 prevalence of 8¢8% in Ethiopia in April 2020 and
25¢4% in Nigeria in August 2020. Both studies had relatively
small sample sizes and used rapid antibody tests. We searched
PubMed up to June 19, 2021, for peer-reviewed and preprints
using the search terms “COVID-19” OR “SARS-CoV-2” AND
“prevalence” AND “Africa”. Additionally, we searched bibliogra-
phies of identified studies, a database of seroprevalence studies
maintained by WHO, and the Google search engine for manu-
scripts and non-peer reviewed pre-prints. We identified three
more studies conducted in Africa reporting SARS-CoV-2 sero-
prevalence estimates for the general population. Prevalence
was 2¢1% in Zambia in July 2020, 38¢5% in South Sudan in
August-September 2020 and 26% in rural and 41% in urban
South Africa in March 2021. The South African study was a
cohort study and estimated the prevalence following the first
and second SARS-CoV-2 wave.
Added value of this study
To our knowledge, this is the first population-based SARS-CoV-
2 prevalence study done in a low-income country in sub-
Saharan Africa, to estimate cumulative SARS-CoV-2 prevalence
after the second wave. Despite lower than predicted hospital-
isations and deaths due to COVID-19 in Zimbabwe, SARS-CoV-2
seroprevalence in the population is extremely high across age-
groups. Seroprevalence more than doubled during the second
wave.
Implications of all the available evidence
This study demonstrates that laboratory-confirmed case notifi-
cations grossly underestimate the true number of infections in
Zimbabwe. The majority of SARS-CoV-2 infections were asymp-
tomatic. These findings are crucially important for future SARS-
CoV-2 control measures and more specifically for vaccination
strategies. If the majority of the population has some immunity
due to past infection, a single-dose vaccination approach may
be an option. Longitudinal studies in low-income settings in
rural and urban populations are urgently needed to understand
optimal vaccination strategies in the context of prior infection.
2 A. Fryatt et al. / EClinicalMedicine 41 (2021) 101172A nationwide lockdown was first implemented on March 30 2020,
confining people to their homes, and restricting movement to a 5 km
radius. All air and land borders were closed to foreign nationals, only
allowing returning residents and nationals to enter the country. Use
of face coverings and social distancing was mandated, and all publictransport, apart from essential state worker transport (e.g. health
care workers), was suspended. The lockdown was extended until
May 17 2020 [2]. A second national lockdown came into force on Jan-
uary 5 until February 19 2021. The lockdown introduced a 6am 
6pm curfew and a ban on public gatherings and intercity travel with
the exception of essential travel including commercial cargo. The sec-
ond wave in Zimbabwe was associated with the emergence of a new
SARS-CoV-2 variant B.1.351 (beta variant) in South Africa [3], which
was subsequently also detected in Zimbabwe [4]. Prior to the ongoing
third wave, a traveller returning from India was found to have a
SARS-CoV-2 infection with the delta variant (B.1.617.2), which is
thought to be more transmissible and likely driving the current third
wave in Zimbabwe [5].
By July 27 2021 Zimbabwe has reported a total of 101,711 con-
firmed SARS-CoV-2 infections and 3280 deaths (Figure 1) [6]. Most
cases and deaths were reported in Harare and Bulawayo, the two
largest cities in Zimbabwe. However, case notification data hugely
underestimate the true number of SARS-CoV-2 infections globally
[7,8]. Many cases may not be identified due to mild or absent symp-
toms and/or reluctance to access care or testing [9,10]. In addition, in
Zimbabwe, where SARS-CoV-2 testing capacity is limited and popula-
tion surveillance is minimal, the gap between the number of reported
cases and the true number of infection is likely to be even larger [11].
Little information is available about the prevalence of SARS-CoV-2
in the general population in Africa [8]. Community-based surveys
from 2020 reported an estimated seroprevalence of 8¢8% in Addis
Ababa in Ethiopia (301 randomly selected people in April 2020) [12],
2¢1% in Zambia (cross-sectional cluster sample survey of households
in 6 districts in July 2020) [13] and 25¢4% in Niger State in Nigeria
(185 randomly sampled people across state in August 2020) [14]. A
longitudinal SARS-CoV-2 seroprevalence survey among the general
population in rural (Mpumalanga Province) and urban communities
(North West Province) in South Africa conducted between July 2020
and March 2021 revealed a prevalence of 7% in rural and 27% in urban
communities after the first wave of SARS-CoV-2 infections and 26% in
rural and 41% in urban communities after the second wave [15].
Differences in population demographics, living conditions, in-
country mobility, risk of virus importation, disease epidemiology,
health system access and climate may affect SARS-CoV-2 epidemiol-
ogy. Large representative population-based seroprevalence surveys
are needed to understand the epidemiology of SARS-CoV-2 in Africa
and estimate infection rates, calculate infection-hospitalisation and
infection-fatality ratios and compare infection burden between
waves. These data are crucial to guide public health responses includ-
ing vaccination strategies.
We report a population-based household SARS-CoV-2 seropreva-
lence survey conducted in three high-density communities in Harare,
Zimbabwe between November 2020 and April 2021. We also com-
pared seroprevalence before (November  December 2020) and after
(February  April 2021) the second wave.2. Methods
2.1. Study design and study population
We conducted a cross-sectional study on randomly selected
households aiming for a total of 2000 participants in three communi-
ties in Harare namely Budiriro, Highfield and Mbare, the largest and
most densely populated communities in the city.
A sample size of 2000, assuming a design effect of 2 for the vari-
ance inflation due to clustering at household level and community
level, was calculated to provide adequate precision around a preva-
lence of 5% (95% CI 3.6-6.4%, precision 1.4%, relative error 28%). Anti-
body prevalence was not expected to be lower than 5% in the
population.
Figure 1. National laboratory confirmed SARS-CoV-2 incident infections and deaths and cumulative laboratory confirmed SARS-CoV-2 infections by province. a Incident SARS-CoV-
2 daily cases (grey) and death (red). The red shading represents the survey periods for the study. b: Cumulative SARS-CoV-2 infections by province. Mash West = Mashonaland
West; Mash East = Mashonaland East; Mash Central = Mashonaland Central; Mat South = Matabeleland South; Mat North = Matabeleland North.
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2021 with a five-week hiatus due to a nationwide lockdown in Janu-
ary 2021 (Figure 1). In Budiriro, survey rounds were conducted before
the second wave (November 20  December 12 2020) and after
(March 23  April 17 2021), with each round aiming to enrol approx-
imately 500 participants. In Highfield one third of the households
were enrolled before the second wave (December 15  20 2020) and
two thirds after (February 10 - 23 2021). Fieldwork in Mbare was
conducted between February 26 and March 21, 2021.
Households were selected through randomly generated GPS coor-
dinates using the QGIS software (version 3.12). All GPS points were
loaded onto the application ‘Maps.Me’ for Android (www.maps.me)
on the researcher’s tablet. Upon arrival the plot closest to the GPS
point was selected for the survey. If on a plot there were multiple
households living in a house, or multiple houses or flats all house-
holds were numbered, and a random number generator (Random
Number Generator Plus by Random Apps Inc.) was used to randomly
select one household.
Individuals of any age who had slept three out of the last seven
nights in the household before the survey team visited were eligible
for participation in the survey. Written informed consent was
obtained from adults and emancipated minors, parental consent was
obtained for participants aged 17 years and younger, and assent was
obtained from participants aged 717 years, before the study. Ethical
approval for the study was obtained from the Medical Research
Council of Zimbabwe, the Institutional Review Board of the Biomedi-
cal Research and Training Institute, and the London School of Hygiene
and Tropical Medicine ethics committee.
2.2. Procedures
For each household, a household-level questionnaire was admin-
istered including information on the number, age and sex of people
living in the household, the number of bedrooms, availability of run-
ning water and soap. For households visited after the second wave
(from February 2021 onwards), information about any visitors stay-
ing in the household overnight and whether or not the visitor had
recently travelled to Zimbabwe from outside the country was also
collected.For each participant, an individual-level questionnaire was
administered that included information about demographics, occu-
pational status, medical history, SARS-CoV-2 exposures, and history
of any symptoms of viral diseases over the past 6 months. From Feb-
ruary 2021 onwards questions about travel and sleepovers in other
households, as well as attendance at large events (>50 people) were
added. All questionnaires were administered using electronic data
capture software (SurveyCTO, https://www.surveycto.com/). Dried
blood spot (DBS) samples were obtained from all consenting partici-
pants using finger prick technique onto a filter card. If household
members were not present at the initial visit, then the research team
arranged two further follow up visits to enrol all members of the
household. If after three visits a household member was still not
present, they were not included.
2.3. Laboratory testing
DBS samples were thoroughly dried overnight, individually
packed in desiccant containing zip-lock bags and stored at -20°C.
Shipping to the Department of Infectious Diseases and Tropical Medi-
cine of the Ludwig Maximillian University Munich was performed at
room temperature. DBS samples were eluted, and anti SARS-CoV-2
nucleocapsid antibodies were measured as described elsewhere [16].
In brief, DBS cards were punched using a Panthera-PuncherTM 9
Instrument (PerkinElmer). Three discs with 3¢2 mm diameter per
DBS spot were automatically dispensed into each well of barcoded
96-well plates. Using two JANUS G3 workstations (PerkinElmer), or
adjustable tip spacing multichannel pipettes (Integra Voyager), elu-
tion buffer was added. Elution was performed in temperature-con-
trolled shakers (MIUlab ES-60E) for 1h at 37°C with 300 rpm. A total
of 80 ml of PBS buffer containing albumin (5%), ammonium thiocya-
nate (2¢5 mM) and Tween 20 (0¢5%), was used to elute antibodies off
the DBS and suppress background. Samples were transferred to
Roche rack packs containing Roche 13/16 micro sample cups
(05085713001) and measured in a Roche e801 machine, using
improved cut-off values [17]. All positive samples were re-tested to
confirm positivity and exclude sample mix ups or other mistakes. A
random sample of 10% of negative samples were also retested. The
assay has a sensitivity of 99.20% and specificity of 98.65% [16].
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Statistical analysis was performed using Stata 15.1 (StatCorp,
Texas, USA). Prevalence was calculated as number of positive tests
divided by number of samples tested, per district and by year (repre-
senting before and after the second wave). Age was categorised in
10-year bands for those aged 10+ years and 5-year bands for those
under 10. Non-response weights were calculated using age band and
sex from the sampling frame of all eligible individuals at participating
households, including those who refused to participate or were
absent. Separately we calculated prevalence by year adjusting for
sensitivity and specificity of the assay [18]. Generalised linear models
were used to calculate prevalence ratios using Poisson regression
with a log link function, adjusting for age band and community. We
adjusted for household level sampling to account for clustering
within households.
2.5. Role of funding source
The funders had no role in study design, data collection and analy-
sis, decision to publish, or preparation of the manuscript. AF, VS, TB,
NR, RAF and KK had access to the data. The decision to submit the
manuscript for publication was a joined decision taken by all authors.
3. Results
Between November 20 and December 20, 2020 (Figure 1), we
approached 208 households and enrolled 202 (97¢1%) with at least
one DBS sample collected in 193 (92¢8%). There were 885 potentially
eligible participants in the enrolled households. Of the eligible partic-
ipants 648 (73¢2%) were consented and interviewed, 628 (71¢0%) pro-
vided a DBS sample and 620 DBS samples (70¢1%) were of high
enough quality to be tested (Figure 2). Between February 10 and April
17, 2021, 506 households were approached and 503 (96¢6%) enrolled.
From a total of 2093 potentially eligible participants, 1692 (80¢8%)
were enrolled. DBS samples were processed for 1530 (73¢1) partici-
pants from 466 (92¢0%) households. Survey participation was higher



















Figure 2. Flowchart of houscompared to those aged 21-49 years (68¢8%) and was higher in
women than men (78¢2% vs. 65¢0%).
In both years, the study included more children and young adults
than older individuals (Table 1). The median age of participants was
22 (IQR 10-37) years and the reported HIV prevalence was 8¢9% (95%
CI 7¢5-10¢5%) in those aged >15 years. The majority of those aged
>15 years were unemployed or self-employed, including street ven-
dors.
In 2020, 19¢0% (95% CI 15¢1-23¢5%) of participants were SARS-
CoV-2 positive and in February-April 2021 the SARS-CoV-2 preva-
lence was 53¢0% (95% CI 49¢6-56¢4). The prevalence ratio was 2¢48
(95% CI 1¢94-3¢16) comparing 2020 with 2021 after adjusting for age,
sex and community (Table 2). Those less than <20 years of age had a
0¢69 (95% CI 0¢62-0¢77) times lower prevalence than those aged 20-
59 years. In the 2021 data, the prevalence ratio for Mbare compared
to the other two communities combined was 1.28 (95% CI 1.13-1.44)
after adjusting for age and sex (Figure 3). After adjusting for sensitiv-
ity and specificity of the assay, the prevalence of SARS-CoV-2 anti-
bodies was 18¢0% (95% CI 14¢1-22¢1%) in 2020 and 52¢8% (95% CI
49¢3-55¢0) in 2021.
Table 3 shows characteristics associated with SARS-CoV-2 seroposi-
tivity in the 2021 survey round, adjusted for age and community. People
who had attended a large event of more than 50 people, such as wed-
dings, funerals, or religious services, in December 2020-January 2021
were 13¢7% (95% CI 1¢0-28¢6%) more likely to be SARS-CoV-2 positive,
and those who reported close contact with a confirmed SARS-CoV-2 case
were 20¢9% (95% CI 3¢2-41¢6%) more likely to be positive, adjusting for
age, location and non-response weighting. There was no association
between SARS-CoV-2 prevalence and sex, education, comorbidities, stay-
ing away from home overnight, having a confirmed SARS-CoV-2 case in
the household, or availability of running water or soap (Table 3). For the
two suburbs that were sampled in both years, the adjusted prevalence
difference comparing the periods before and after the second wave was
27¢0% (95% CI 22¢5-31¢6). This represents the cumulative incidence
between the twowaves. Table 4 shows the prevalence of reported symp-
toms by SARS-CoV-2 antibody status. Almost half of participants testing
positive for SARS-CoV-2 antibodies (49¢7%) reported no symptoms
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Participants’ characteristics in 2020 and 2021
Characteristics Survey in 2020 Survey in 2021
N % (95% CI) N % (95% CI)
N=620 N=1530
Suburb Highfield 160 22¢6 (16¢6, 29¢9) 369 22¢2 (18¢2, 26¢8)
Budiriro 460 77¢4 (70¢1, 83¢4) 546 38¢3 (33¢4, 43¢5)
Mbare 0 0 615 39¢5 (34¢5, 44¢7)
Sex Male 259 45¢6 (41¢7, 49¢4) 623 45¢5 (43¢2, 47¢9)
Female 361 54¢5 (50¢5, 58¢2) 907 54¢5 (52¢1, 56¢8)
Age 0-4 68 13¢1 (10¢5, 16¢2) 125 8¢6 (7¢4, 10¢4)
5-9 89 13¢1 (11¢6, 16¢1) 200 11¢9 (10¢5, 13¢4)
10-19 133 20¢9 (17¢9, 24¢2) 325 20¢5 (18¢5, 22¢6)
20-29 106 16¢2 (13¢1, 19¢8) 292 20¢3 (18¢1, 22¢6)
30-39 105 16¢5 (13¢8, 19¢6) 223 15¢5 (13¢7, 17¢5)
40-49 69 11¢9 (9¢4, 14¢9) 148 10¢9 (9¢3, 12¢6)
50-59 22 3¢4 (2¢2, 5¢3) 111 6¢4 (5¢2, 7¢7)
60-69 20 3¢4 (2¢1, 5¢5) 67 3¢7 (2¢9, 4¢7)
70-100 8 1¢0 (0¢5, 2¢2) 39 2¢3 (1¢6, 3¢2)
Household size Median (IQR) - 4 (3-5) - 4 (3-5)
Education (missing for 23) None 76 13¢1 (10¢7, 16¢0) 149 9¢5 (8¢2, 11¢0)
Primary 171 28¢6 (24¢9, 32¢6) 380 23¢8 (21¢7, 25¢9)
Secondary 299 48¢0 (44¢0, 52¢1) 868 57¢9 (55¢3, 60¢4)
Diploma 33 5¢6 (3¢9, 8¢0) 57 4¢1 (3¢1, 5¢3)
University 28 4¢6 (3¢0, 7¢1) 66 4¢8 (3¢6, 6¢3)
Employment status if aged 16 (missing for 29) Student 51 13¢9 (10¢7, 17¢9) 112 11¢0 (9¢0, 13¢3)
Formally employed 76 22¢3 (17¢8, 27¢4) 194 21¢0 (18¢2, 24¢1)
Street vendor 47 12¢7 (9¢6, 16¢5) 147 14¢2 (11¢9, 16¢7)
Other self-employed 67 19¢1 (15¢1, 24¢0) 143 15¢7 (13¢0, 18¢7)
Unemployed 125 32¢1 (27¢3, 37¢2) 403 38¢2 (34¢9, 41¢5)
Primary mode of transport if aged 16 (missing for 36) Private 59 17¢5 (13¢4, 22¢6) 177 18¢1 (15¢4, 21¢3)
Public 238 66¢2 (59¢9, 72¢0) 558 55¢7 (51¢9, 59¢5)
Walking 58 16¢2 (12¢0, 21¢6) 268 26¢1 (22¢9, 29¢6)
Does the household have running water from the tap? Almost never/no 263 43¢9 (36¢0, 52¢1) 300 20¢8 (16¢8, 25¢3)
Intermittently 222 36¢1 (28¢7, 44¢2) 617 39¢9 (34¢9, 45¢1)
All the time 135 20¢0 (14¢4, 27¢1) 613 39¢3 (34¢4, 44¢5)
Medical condition (missing for 23) Hypertension 26 4¢0 (2¢7, 5¢9) 102 6¢0 (4¢9, 7¢4)
Diabetes 7 1¢1 (0¢5, 2¢3) 26 1¢6 (1¢1, 2¢4)
HIV 20 3¢4 (2¢1, 5¢4) 116 7¢2 (5¢9, 8¢9)
Ever had a SARS-CoV-2 positive PCR? (missing for 23) Yes 22 4¢0 (2¢5, 6¢4) 96 6¢8 (5¢4, 8¢4)
Close contact (<1m) with laboratory confirmed SARS-CoV-2 case?
(missing for 23)
Yes 15 2¢4 (1¢2, 4¢7) 96 6¢8 (5¢1, 9¢0)
Any deaths in the household within the previous 6 months Yes 48 7¢5 (4¢3, 12¢6) 98 6¢3 (4¢3, 9¢2)
Percentages and confidence intervals are weighted for non-response
Table 2
Weighted prevalence of SARS-CoV-2 antibody positivity
Characteristics Prevalence (95% CI) Adjusted prevalence
ratio (95% CI)
p-value
Age <20 33¢4 (29¢6, 37¢4) 0¢69 (0¢62, 0¢77) <0¢001
20-59 50¢4 (46¢8, 53¢9) 1
60+ 47¢0 (37¢9, 56¢2) 0¢89 (0¢74, 1¢06)
Sex Male 43¢6 (39¢7, 47¢5) 1 0¢39
Female 42¢3 (38¢9, 45¢9) 0¢96 (0¢88, 1¢05)
Year 2020 19¢0 (15¢1, 23¢5) 1 <0¢001
2021 53¢0 (49¢6, 56¢4) 2¢48 (1¢94, 3¢16)
Location Budiriro 34¢7 (30¢5, 39¢2) 1 <0¢001
Mbare 61¢2 (56¢0, 66¢2) 1¢26 (1¢09, 1¢46)
Highfield 38¢4 (33¢1, 44¢0) 0¢97 (0¢82, 1¢16)
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According to our data one in two people (53.0%, 95% CI 49¢6-
56¢4%) had been infected with SARS-CoV-2 by April 2021 in three
high density communities in Harare, Zimbabwe. The seroprevalence
survey results suggest that 184,800 (172,900-196,700) SARS-CoV-2
infections occurred in these three communities alone, which greatly
exceeds the reported number of cases for the whole city (13,044 on
April 19 2021). Unfortunately, notified SARS-CoV-2 infections areonly reported by province and notifications by district or subdistrict
are not available. Hence direct comparisons between the number of
infections estimated from the seroprevalence survey and notification
data are difficult. The three communities have an estimated popula-
tion of 350,000, which accounts for 19% of the population in the capi-
tal [19,20]. If seroprevalence was similar across Harare, almost
1 million (972,631) SARS-CoV-2 infections would have occurred dur-
ing the first and second wave. Thus the ratio of serologically detected
infections to confirmed SARS-CoV-2 cases in Harare is likely to be
much higher than that reported from South Africa [15] (18¢0-27¢1)
but similar to data from Juba, South Sudan with an estimated ratio of
more than 100 [21]. The cumulative incidence estimate of 27.0% sug-
gest that 68,500 new SARS-CoV-2 infections occurred during the sec-
ond wave in Budriro and Highfield alone, while the number of
infections reported in Harare during the second wave was only 8700.
Our data confirm that there has been extensive community trans-
mission during the first and second wave. The data from two commu-
nities in Harare showed that 18¢0% (95% CI 14¢1-22¢1%) of the
population had been infected with SARS-CoV-2 following the first
wave. The prevalence of past infection was highest among the 3039
year age-group with no difference between men and women, which
is comparable to other data from sub-Saharan Africa [14,15,21].
SARS-CoV-2 seroprevalence more than doubled during the second
wave, confirming intense community transmission. Factors that may
have contributed to high levels of community transmission especially
Figure 3. Prevalence of SARS-CoV-2 and 95% CIs by year, age group, sex and suburb. Black = 2020, red = 2021
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travel as restrictions were being eased in December 2020, a national
public holiday (Christmas) resulting in inter-generational mixing and
travelling to and from rural villages for family reunions, and the
emergence of a more transmissible SARS-CoV-2 variant B.1.351 (beta
variant) in South Africa [3]. This was also reflected in the higher num-
ber of laboratory confirmed SARS-CoV-2 infections and deaths during
the second wave compared to the first wave [22].
Following the second wave, SARS-CoV-2 seroprevalence was
higher in the population of Mbare compared to the prevalence in the
other two communities. Mbare is the oldest high-density community
in Harare, established in 1907, and home to a major trading market
(Mbare Musika) and bus station for intercity transport. In contrast to
the other two communities, Mbare has many blocks of flats built in
the 1940s as “hostels”. The capacity of those flats is greatly surpassed
with occupancy rates for single rooms sometimes going up to 2-3
households [23]. The proximity of Mbare to the central business dis-
trict of Harare, the working and trading opportunities provided by
Mbare Musika and the transport hub results in movement in and out
of Mbare from the other provinces. This may explain the higher sero-
prevalence in Mbare compared to the other two communities.
The proportion of individuals reporting previous symptoms of flu-
like illness was higher among those with positive SARS-CoV-2 serol-
ogy compared to those with a negative serology. However, almost
half of those with positive serology did not remember any symptoms
in the 6 months prior to the survey. This is in line with a high propor-
tion of asymptomatic or mildly symptomatic SARS-CoV-2 infections
especially among young people [9,24,25], but may also be explained
by people failing to remember any symptoms. Few people reported a
PCR-confirmed SARS-CoV-2 infection in the past. No difference in the
proportion of seropositivity between people diagnosed with HIV,
hypertension and/or diabetes was observed. Although individuals
with co-morbidities are more likely to require hospital admission,
their risk of getting infected is likely comparable to those without co-
morbidities.
Those with a positive serology were more likely to have had con-
tact with a person with confirmed SARS-CoV-2 infection andattended large events with more than 50 people  even though most
of these events took place outdoors. Most households had at least
intermittent access to soap and/or hand sanitisers and masks, while
access to running water was available in Highfield and Mbare only.
The strengths of our survey include the relatively large sample
size and high household participation rates. Furthermore we used a
testing methodology which has been rigorously validated on thou-
sands of paired serum and DBS samples [17]. All samples testing posi-
tive underwent a repeat test and a random sample of negative
samples were retested.
Our study has several limitations. While we recruited more than
95% of approached households, we only obtained DBS samples from
72¢2% of potentially eligible study participants. Reasons for not being
able to obtain a DBS sample was refusal by the study participant or
absenteeism. Similar to other surveys, men aged 20-49 years were
less likely to be included in the survey as they were away from the
households for work [15,21]. However, we accounted for that in the
overall seroprevalence estimate. We relied on self-reporting of labo-
ratory confirmed SARS-CoV-2 infection, HIV, diabetes and hyperten-
sion which may be unreliable and subject to underreporting due to
stigma. We did not collect data on socio-economic status. We esti-
mated the cumulative SARS-CoV-2 incidence during the second wave
by comparing results of two cross-sectional surveys. A cohort design
may have been more appropriate, but subject to attrition bias. The
seroprevalence survey was restricted to three communities in Harare
and hence the results are not generalisable to other more rural set-
tings, where transmission may have been less intense. Also the sero-
prevalence survey was restarted on February 10 2021 at a time when
SARS-CoV-2 notifications had just decreased to pre-wave levels.
Hence we may have underestimated seroprevalence post second
wave in Highfield because some individuals with recent or current
infection may not yet have seroconverted. Seroprevalence may have
been underestimated due to antibody decay over time [26].
In conclusion, we found evidence of an extremely high rate of
SARS-CoV-2 infections in three high density communities in Harare
following the second SARS-CoV-2 infection wave. Prevention and
control measures such as contact restrictions (lockdowns and school
Table 3
Generalised linear model of factors associated with COVID antibody positivity in 2021, adjusting for household level sampling
Characteristics Weighted prevalence (95% CI) Prevalence ratio (95% CI)a p-value
Age 0-4 39¢8 (31¢6, 48¢7) 1
5-9 37¢0 (30¢1, 44¢4) 0¢94 (1¢09, 1¢54)
10-19 49¢3 (43¢4, 55¢2) 1¢24 (0¢99, 1¢54) <0¢001
20-29 61¢7 (55¢7, 67¢3) 1¢54 (1¢23, 1¢90)
30-39 60¢4 (53¢3, 67¢1) 1¢52 (1¢21, 1¢90)
40-49 59¢7 (51¢1, 67¢8) 1¢51 (1¢18, 1¢92)
50-59 53¢0 (42¢8, 62¢9) 1¢33 (0¢99, 1¢74)
60-69 61¢3 (49¢7, 71¢7) 1¢51 (1¢16, 1¢97)
70-100 47¢3 (31¢1, 64¢0) 1¢15 (0¢76, 1¢79)
Location Budiriro 48¢6 (42¢6, 54¢5) 1 <0¢001
Mbare 61¢2 (56¢0, 66¢2) 1¢25 (1¢08, 1¢45)
Highfield 46¢1 (40¢3, 51¢9) 0¢94 (0¢79, 1¢12
Sex Male 54¢3 (49¢9, 58¢6) 1 0¢25
Female 51¢8 (47¢9, 56¢0) 0¢95 (0¢86, 1¢04)
Education (missing for 23) None 39¢6 (31¢9, 47¢8) 1 0¢42
Primary 43¢8 (38¢1, 49¢6) 1¢03 (0¢71, 1¢50)
Secondary 57¢4 (53¢5, 61¢2) 1¢13 (0¢75, 1¢69)
Diploma 69¢2 (54¢4, 80¢9) 1¢32 (0¢85, 2¢05)
University 60¢6 (46¢6, 73¢0) 1¢18 (0¢74, 1¢89)
Any comorbidity (HIV, hypertension or diabetes) (missing for 23) Yes 52¢7 (49¢1, 56¢3) 0¢92 (0¢79, 1¢08) 0¢31
No 55¢7 (48¢6, 62¢5) 1
HIV (missing for 23) Positive 55¢8 (46¢0, 65¢2) 0¢91 (0¢76, 1¢09) 0¢31
Negative 52¢9 49¢4, 56¢3) 1
Diabetes (missing for 23) Yes 55¢6 (35¢4, 74¢1) 0¢97 (0¢69, 1¢37) 0¢88
No 53¢0 (49¢6, 56¢4) 1
Hypertension (missing for 23) Yes 58¢0 (47¢9, 67¢6) 1¢02 (0¢84, 1¢23) 0¢85
No 52¢8 (49¢3, 56¢2) 1
Attended a large event between Dec 2020-Jan 2021 Yes 61¢6 (55¢1-67¢6) 1¢14 (1¢01, 1¢29) 0¢037
No 51¢0 (47¢2-54¢8) 1
Stayed away from home overnight between Dec 2020-Jan 2021 Yes 57¢1 (51¢3-62¢7) 1¢06 (0¢94, 1¢19) 0¢35
No 52¢1 (48¢2-55¢9) 1
Confirmed COVID-19 in household since Dec 2020 Yes 57¢4 (41¢1, 72¢2) 1¢00 (0¢76, 1¢30) 0¢98
No 53¢2 (49¢7, 56¢6) 1
Overnight visitor to the household between Dec 2020-Jan 2021 Yes 57¢0 (50¢6, 63¢1) 1¢06 (0¢93, 1¢21) 0¢36
No 51¢8 (47¢8, 55¢9) 1
Close contact with a confirmed COVID-19 case Yes 67¢9 (57¢3, 76¢9) 1¢21 (1¢03, 1¢42) 0¢017
No 52¢0 (48¢5, 55¢5) 1
Household has running water coming from the taps Almost never 51¢4 (43¢4, 59¢2) 1¢03 (0¢83, 1¢27) 0¢67
Intermittently 51¢2 (46¢1, 56¢2) 0¢95 (0¢83, 1¢09)
All the time 55¢8 (50¢2, 61¢1) 1
Soap or sanitiser readily available in the household Almost never 59¢8 (34¢2, 81¢0) 1¢18 (0¢75, 1¢84) 0¢35
Intermittently 48¢6 (41¢2, 56¢0) 0¢90 (0¢76, 1¢06)
All the time 53¢8 (50¢0, 57¢6) 1
a adjusted for age band and location
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improved case detection were either not sufficiently timely (i.e. too
late) or effective in limiting transmission. In Mbare, the proportion of
individuals with evidence of past infection was more than 60%, which
is close to the community infection threshold. However, new variants
and waning immunity may mean that re-infection and onward trans-
mission of individuals previously infected is possible.
Also, other more rural parts of the country are unlikely to have
equally high rates of past SARS-CoV-2 infections. The third waveTable 4
Reported symptoms in the previous 6 months by SARS-CoV-
2 antibody status
Symptom Negative, n (%) Positive, n (%)
N 1208 919
Cough 232 (19¢2) 251 (27¢3)
Cold 363 (30¢1) 370 (40¢3)
Fever 117 (9¢7) 151 (16¢4)
No sense of smell 42 (3¢5) 71 (7¢7)
Shortness of breath 32 (2¢7) 61 (6¢6)
Any symptoms 468 (38¢7) 462 (50¢3)
*excluding 23 tests with no symptoms questionnaire (17
negative, 6 positive)which seems to be disproportionally affecting the Mashonaland West
province may be explained by that [18]. Ongoing seroprevalence
combined with molecular infection surveys across different settings
are important to inform vaccination strategies and future public
health response.Funding
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